CALGARY, AB, June 22, 2021 /PRNewswire/ – Decibel Cannabis Company Inc. (the “Company” or “Decibel”) (TSXV: DB) (OTCQB: DBCCF), a premium cannabis producer, is pleased to announce  the appointment of Paul Wilson as its Chief Executive Officer, effective Wednesday, June 23^rd.

Emphasizing the Company’s objective for brand growth, Mr. Wilson brings CEO and President level experience from some of Canada’s top consumer brands and is currently a member of Decibel’s board of directors. Mr. Wilson served as CEO, President, EVP, and Officer for consumer businesses, including leadership roles at Canadian Tire, Mark’s, Princess Auto, Spence Diamonds and Alcanna Nova Cannabis. As an experienced brand builder, Mr. Wilson has a consistent winning record in sectors ranging from hard goods to apparel and in formats ranging from start-ups and small chains to department stores and national chains.

“We are excited to continue our momentum with this key appointment. We were intent on adding a CEO who would complement our existing strategy and excellent management team” said Cody Church Chairman and interim CEO of Decibel. “The appointment follows a long and intensive search process that considered exceptional internal and external candidates. The focus of the search reflected the priorities of Decibel and the characteristics needed to address them. With Paul, we have selected a strategic leader and brand builder, with Decibel experience at the Board level.”

Paul Wilson commented “the Canadian cannabis industry is now coming together with the appropriate balance of resources to serve consumers. Decibel has done an exceptional job establishing premium brands like Qwest and Qwest Reserve, with production and supply capability to fulfill a significant segment of the rapidly evolving marketplace. I’m excited to be a part of this brand and this team, with a mandate to further strengthen and increase the value our shareholders have recognized.”

“I’d also like to thank the board of directors for its confidence and more importantly acknowledge the existing management team at Decibel who have established and grown our portfolio of brands as market leaders”, added Mr. Wilson.

About Decibel

Decibel is uncompromising in the process and craftsmanship needed to deliver the highest quality cannabis products and retail experiences. Decibel has three operating production houses along with its wholly owned retail business, Prairie Records. The Qwest Estate in Creston, BC is a licensed and operating 26,000 square foot cultivation, processing and distribution space which produces the widely championed, rare cultivar-focused brands Qwest and Qwest Reserve, which are sold in six provinces across Canada. The Thunderchild Cultivation Facility, is a licensed and operating 80,000 square foot indoor cultivation facility in Battleford, SK. The Plant, Decibel’s extraction, processing and manufacturing facility, in Calgary, AB has 15,000 square feet of Health Canada licensed extraction and product development space. This production house will fuel the growth of our brands Qwest, Qwest Reserve, and Blendcraft, into new and innovative product formats like concentrates, vapes, edibles and beyond.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements

Forward Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

In this news release, forward-looking statements relate to, among other things, the Company’s expectations regarding its ability to bring a significant pipeline of new and innovative products to the market, the Company’s ability to grow Qwest, Qwest Reserve and Blendcraft brands into new and innovative product formats, variations and its other business plans and expectations. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: risks relating to delays, regulatory changes and impacts, capital requirements, construction impacts, displacement requirements and unforeseen requirements resulting from the COVID-19 pandemic, the ability to obtain and maintain licences to retail cannabis products; review of the Company’s production facilities by Health Canada and maintenance of licences (including any amendments thereto) from Health Canada in respect thereof; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the labour market generally and the ability to access, hire and retain employees; general business, economic, competitive, political and social uncertainties; the satisfaction of conditions precedent under the Company’s credit facilities; timing and completion of construction and expansion of the Company’s production facilities and retail locations; and the delay or failure to receive board, regulatory or other approvals, including any approvals of the TSX Venture Exchange, as applicable. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, the Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

These forward-looking statements are made as of the date of this press release and the Company disclaims any intent or obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE Decibel Cannabis Company Inc.

Related Links

https://decibelcc.com/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

LANGLEY, BC / ACCESSWIRE / May 10, 2021 / Phyto Extractions Inc. (formerly, Adastra Labs Holdings Ltd.) (CSE:XTRX)(Frankfurt:D2EP) (“Phyto Extractions” or the “Company”) is proud to announce Michael Forbes Pharm, MBA as its new CEO and director.

Mr. Forbes comes to Phyto Extractions with a background firmly rooted in medicine, cannabis production and entrepreneurship. Demonstrating his knowledge and experience in the cannabis industry, Mr. Forbes has founded five cannabis medical clinics under the Concord Medical Clinic umbrella, built Clarity Cannabis and Honeycomb Cannabis to over 10 locations, and also founded the cannabis licensed production facility, Sitka Weed Works, in Canada.

“I am honored to have been selected to serve as the new CEO and look forward to overseeing the execution of the corporate vision of continued leadership in the recreational cannabis space through the development of brand offerings that position us as the clear choice in the mind of cannabis consumers now and in the future,” said Michael Forbes, CEO. “My experience in health care, medicine, business operations and cannabis will be integral to continuing to strengthen the company’s current position and planned expansion into the burgeoning medical market.”

Having medical experience of over 16 years, Mr. Forbes has also built and operated pharmacy chains across British Columbia and Alberta, and founded a dozen medical clinics, including 3 methadone clinics in order to protect the public from drug diversion and increase accessibility to medicine.

Mr. Forbes graduated from the University of British Columbia in 2002 with a BSc. in Pharmaceutical Sciences, also achieving additional certification in Hormone Restoration, Age Management Medicine, and more recently, Cannabis Plant Production and Facility Management from Kwantlen Polytechnic University. He was elected to attend the Ivey School of Business for Canada’s Top 40 under 40 in 2017 where he received an honorary MBA.

In other corporate news, Donald Dinsmore, the Chief Operating Officer of the Company, was appointed as an additional director to fill the vacancy created by the prior resignation of Blaine Bailey. Following such changes, the board of directors consists of Michael Forbes, Donald Dinsmore, Stephen Brohman and George Routhier.

About Phyto Extractions

Phyto Extractions is an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction and products, no cultivation), Sales (extracts, topicals, and edibles), and R&D through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc.

ON BEHALF OF THE BOARD
PHYTO EXTRACTIONS INC.

Per: “Donald Dinsmore”
Donald Dinsmore
Chief Operating Officer and Director
Phone: (778) 715-5011

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The psychedelics industry has experienced a renaissance over the past few years as researchers have opened a pandora’s box of potential. From major depression to generalized anxiety to post-traumatic stress disorder, emerging research suggests that psychedelic substances could have a significant beneficial impact on hard-to-treat mental health disorders.

As states liberalize their psychedelics regulations, microdosing has become a popular trend that could offer a variety of mental health benefits. Research on microdosing remains in its infancy, but the combination of placebo-controlled studies and effective delivery systems could translate to a larger-scale trend over the coming years.

Let’s take a closer look at microdosing and how new technologies are making it easier to achieve a consistent result.

What is Microdosing?

Microdosing is the practice of consuming a very low, sub-hallucinogenic dose of a psychedelic substance, such as psilocybin or LSD. While scientific literature contains minimal research, there is plenty of anecdotal evidence to support the practice but the handful of high-quality studies that do exist paint a mixed picture of microdosing efficacy.

In 2018, the Imperial College of London conducted the first placebo-controlled study of microdosing practices. Participants received either a psychedelic or placebo and completed online surveys and cognitive tasks at regular intervals. The results showed improvements in both the psychedelic and placebo groups with no significant differences between them.

Other researchers believe that microdosing may still offer tangible benefits. Maastricht University researchers in the Netherlands conducted their own small-scale placebo-controlled study and found beneficial effects on mood and attention for some participants that couldn’t be explained by the placebo effect. They suggest that timing could be an important factor.

The same researchers from Maastricht University measured brain-derived neurotrophic factor (BNDF)—a protein that affects brain plasticity—and found an increase a few hours after microdosing psychedelics in blood tests. These findings suggest that there is some kind of physiological factor at play with microdosing practices.

 Ensuring the Right Dose

The varying effects of microdosing practices could be the results of varying metabolic rates and drug delivery mechanisms. For instance, capsule-based forms of microdosing involve swallowing a pill that is subject to second-pass metabolism in the liver. Sublingual delivery mechanisms, on the other hand, quickly move to the brain. 

Revive Therapeutics Ltd. (CSE: RVV) is building an intellectual property portfolio around psychedelic drug delivery. After acquiring Psilocin Pharma Corp., the company partnered with Complete Phytochemical Solutions and signed a sponsored research deal with the University of Wisconsin-Madison to develop new delivery methods for psychedelic substances.

The company’s dissolvable oral strips could be especially beneficial for microdosing, delivering between one and 20 milligrams of natural or synthetic psilocybin with rapid onset that bypasses liver metabolism. The company’s other products targeting both psychedelics and cannabinoids include lozenges, gels, creams and transdermal patches. 

While many companies undergo expensive clinical trials, the company’s innovative delivery systems could see a faster path to commercialization as California, Oregon and other states start to legalize psychedelics for personal use. These efforts could open the door to widespread microdosing practices to realize cognitive and other mental health benefits.

Looking Ahead

Investors interested in the psychedelics space may want to consider companies focused on microdosing practices since they could represent a nearer-term path to commercialization. Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) is a prime example with its dissolvable oral strip delivery system for psilocybin microdosing.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

May 29, 2020 — Santa Monica, CA — CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announces an article discussing Israel’s recent approval for cannabis exports and how companies like Isracann Biosciences, Inc. (CSE: IPOT) (OTC: ISCNF) are well-positioned to profit.

Israel gave final approval in mid-May for exports of medical cannabis, paving the way for more than one billion shekels ($273 million) in annual revenue. The country will become one of just three countries that have approved the export of medical cannabis to countries that permit its use—after Canada and the Netherlands— when the law goes into effect on June 13, 2020.

With its favorable climate and expertise in medical and agricultural technologies, Israel could become one of the world’s biggest producers of medical cannabis. iCAN estimates the global market for Israel’s medical cannabis could be as high as $33 billion, while Israeli companies like Syqe Medical have pioneered innovative medical cannabis technologies.

The go-ahead to export medical cannabis could open the door to new investment in the country, while existing Israeli producers, like Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF), could be well-positioned to benefit from near-term export demand.

Click Here To Receive Isracann’s Investor Presentation 

Let’s take a look at who stands to profit from the recent export decision and how investors can position themselves to capitalize on the developments.

Who Stands to Profit?

There are more than ten farms and five factories in Israel that meet the Health Ministry’s standards for medical cannabis exports, and several of them have already reached agreements to sell cannabis to Europe or Canada when licenses become available.

Isracann Biosciences Inc. (CSE: IPOT) (OTCQB: ISCNF) is Israel’s first pure-play cannabis firm wholly focused on becoming the nation’s premier, low-cost cannabis producer. The company has a joint venture agreement in place with a built 55,000 sq. ft. farm that’s expandable to 110,000 sq. ft. in the near-term and has access to over two million sq. ft. of private land.

“Our Hefer Valley farm is making great strides,” said Isracann’s VP of Operations, Matt Chatterton in a recent press release. “We engaged a specialist Israeli consultant to advance the certification of farm to EU-GMP standards thereby paving the way for our export distribution. In addition, the related post-harvest export facility is nearing readiness.”

In addition to its production, Isracann entered into a MOU earlier this year to distribute cannabis throughout European end markets. The distributor will import products through the Republic of Malta, subject to compliance and regulations, and is currently preparing a regional processing facility designed to meet EU-GMP standards.

Breath of Life International Ltd. planned to raise C$150 million on the Toronto Stock Exchange (TSE) through a public share offering priced at C$27 to C$32 per share last year, but management shelved plans for an IPO until market conditions improved in October 2019. The company reported $1.1 million in revenue during the first quarter of 2019 from the Israeli market.

Click here to view an exclusive interview with Isracann’s CEO Darryl Jones:

Click Here To Receive Isracann’s Investor Presentation 

Other Israeli cannabis producers that could benefit include:

• Cronos Group Inc. (TSX: CRON) has a strategic joint venture with Kibbutz Gan Shmuel, a commercial farming community, whereby it plans to build a 45,000 sq. ft. greenhouse in Israel that will help supply the European market.
• Aura Health Inc. CSE: BUZZ) holds convertible debt that converts to a 54% equity position in HolyCanna, a cultivation and nursery license in Israel. The company also signed a LOI with CannabiSendak to build a high-profile dispensary in Tel Aviv.
• Namaste Technologies Inc. (TSX-V: N) owns a 10% stake in Cannbit, a licensed cannabis operation in Israel. The company also has a collaboration and supply agreement with the company to purchase medical cannabis.

What’s Next for Israel?

Israel’s move to legalize medical cannabis exports could be transformative for many public and private companies operating in the country. Investors looking for exposure to the space may want to consider Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) as one of the only pure-plays in the space or a handful of other companies that have exposure through joint ventures and investments.

Learn more about Isracann Biosciences by downloading their investor presentation or visiting their website.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Cannabis investors had already been shifting from “unproven potential” to “profitability” over the past several quarters prior to the global health crisis. With the COVID-19 outbreak, investors have fled previous investments to profitable companies that aren’t reliant on costly or dilutive funding to sustain their operations.

THC BioMed Intl Ltd. (CSE: THC) recently recorded its second consecutive quarter of profitability along with more than $1 million in revenue. This represents profits of $88,191 for the three months ended January 31, 2020. Investors looking for exposure to the cannabis industry may want to take a closer look at the stock as an alternative to companies with high cash burn rates and losses in operations.

Click Here To Receive Updates on THC BioMed

Growing Revenue & Outlook

THC BioMed generated more than $1 million in revenue during the first two quarters of fiscal year 2020 with an average selling price of $4.20 per gram to medical patients and recreational buyers, including the Ontario Cannabis Store and BCcannabisonline. During the second quarter alone, revenue rose 163% year-over-year to $1,246,625.

“Over the last year, we have completed and started using new grow rooms to increase our output,” said President & CEO John Miller. “Our focus on high-quality, indoor-grown cannabis at reasonable prices has made our cannabis a best seller.”

The company achieved several key operational milestones over the past six months:

Sales of THC Kiss began on April 10, 2020. The cannabis beverage can be purchased by THC BioMed’s medical patients via the company’s online store.
Pure Cannabis Sticks — or filtered, paper cylinder pre-rolls — went into automated production.
A new three-year lease was signed for a property adjacent to the company’s production facility, which will be used to free up space for more production.
Its Cannabis Act license was amended to include the production and sale of cannabis edibles, topicals and extracts, opening the door to new markets.

Management believes that these operational milestones pave the way for revenue growth over the coming quarters. In particular, the launch of Cannabis 3.0 products will expand the company’s addressable market, while the production efficiencies offered by Pure Cannabis Sticks boost bottom line performance.

Click Here To Receive Updates on THC BioMed

Sustainable Profitability

THC BioMed reported net income of $88,191, gross profit before fair value adjustments of $759,959, and adjusted EBITDA of $131,549 during the second quarter, representing its second consecutive quarter of profitability—a rarity among licensed producers that have historically experienced a high cash burn rate.

Second quarter net income was lower than the $688,925 reported during the first quarter on the surface, but gross profit before fair value adjustments and adjusted EBITDA were higher than first quarter levels of $295,480 and $890, respectively. These figures suggest that the actual bottom line performance has improved quarter over quarter.

“We are proud to have achieved our second consecutive profitable quarter,” added Mr. Miller. “Our financial statements for Q2 2020 reflect the improvements we have realized in all key indicators of economic progress.”

It’s worth noting that the average price of $4.20 per gram is lower than the average prices reported for other licensed producers, which makes the profitability even more significant, as margins are lower than the competition. If industry average prices trend lower, the company doesn’t have to cut its prices in order to remain competitive.

Looking Ahead

THC BioMed Intl Ltd. (CSE: THC) is one of the few profitable licensed producers in the industry, giving them an edge over other companies that are reliant on potentially dilutive future fundraising to stay alive.

Click Here To Receive Updates on THC BioMed

Click here to read the full feature: https://bit.ly/2V2r0Se

THC BioMed Contact:
CEO: John Miller
[email protected]
844-842-6337

CFN Media Contact:

President Frank Lane
[email protected]
206-369-7050

About CFN Media
CFN Enterprises Inc. (OTCQB: CNFN) is the owner and operator of CFN Media, the leading agency and digital financial media network dedicated to the legal cannabis, CBD & Psychedelic industries.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

What is the ideal setting for a brand to showcase its wares to the retail consumer? It is certainly not a crowded store with hundreds of brands competing for limited shelf space and consumer attention. Every brand out there would much rather have its own store, featuring its own product offerings, staffed by expert sales associates ready to educate consumers on the value of their products. In short, every brand would like its own version of the Apple Store or the Gap. Of course, every brand can’t afford to develop its own store, and cannabis licensing requirements often make the idea even more untenable.

CalEthos may have the answer for cannabis brands struggling to solve this problem. The company is currently financing the first of several planned cannabis superstores, appropriately called SHOWCASE, in Southern California. The concept is to provide partner cannabis brands their own space within a 20,000 sq. ft. SHOWCASE footprint, allowing them to fully display all that a brand has to offer. Each SHOWCASE location will also feature a medical pharmacy, an event center for community and consumer education, and a cafe and lounge areas to enhance the consumer experience and extend the shopper’s stay. Rather than the cramped, hurried environment common throughout retail cannabis, SHOWCASE promises to cater to both the customer and the brand in an elevated, inviting space.

CalEthos President Piers Cooper sat down with CFN Media to discuss the ideal setting for retailers to SHOWCASE their cannabis brand. Please click on the video below for the full story.

Click Here to Receive a CalEthos Investor Presentation & Company Updates

Click below to hear CalEthos’ President Piers Cooper discuss the SHOWCASE concept

CalEthos Did the Homework

The two executives largely responsible for the CalEthos concept, CEO Michael Campbell and President Piers Cooper, have a long history in advising, building, and investing in companies both private and public. They kept bumping up against the emerging cannabis industry and decided to investigate, looking for opportunities arising from shortcomings in the young marketplace. They settled on retail, visiting a wide variety of stores and brands and talking to everyone involved, from the consumer to the staff to the product companies.

These investigations highlighted the problems listed above, both for the brand and for the consumer. Cannabis has been legalized, but many stores still carry a bit of a black-market vibe which is uninviting to newer cannabis consumers. Space is at a premium, as most dispensaries don’t have the capital to build large format stores or expand and upgrade existing stores. Budtenders are generally helpful, but they are usually limited to some personal advice about a brand they like before making the sale and moving on to the next in line.

Click Here to Receive a CalEthos Investor Presentation & Company Updates

From the brand side, it is almost impossible to build a loyal customer base under such conditions. With advertising options limited, brands don’t have anywhere to turn. A given dispensary may carry 5 out of the brand’s 50 SKUs, whilst those 5 products are generally displayed amongst many other brands with limited space or capability for differentiation.

Campbell and Cooper came away from their research knowing there had to be a solution that provided a better consumer experience while enabling product makers to actively engage and educate those consumers.

Click below to hear CalEthos’ President Piers Cooper discuss The SHOWCASE Model Inspiration

The SHOWCASE Solution

CalEthos enlisted the help of Stephen Brady, the man responsible for the design of numerous Ralph Lauren, Bloomingdales, Gap, Old Navy, Banana Republic and other retail stores. Brady helped them realize the vision of an open, engaging, vital retail setting in which consumers are given space and options and educational opportunities. CalEthos is tuned in to the need to invite and educate ‘canna-curious’ consumers, and the SHOWCASE design enables that with event and education space along with lounge areas and a cafe. The concept is not turn and burn, though there is nothing stopping a customer from grabbing what they need and leaving quickly. Rather, the concept is explore and learn and enjoy. CalEthos believes consumers will gravitate to its model over the typical marijuana dispensary in the Southern California market.

Rendering of CalEthos SHOWCASE retail store

The company already knows that brands will appreciate the opportunity to create their own stores-within-a-store. Brand partners can procure dedicated space under the SHOWCASE Brand Membership Program that ranges from a 10’ x 16’ boutique with 90’ of shelf space, to shared kiosks in specialty product sections with 21’ of shelf space per brand, to 18’ of refrigerated shelf space in the Chill Zone for edibles and beverages. The SHOWCASE design also features a pharmacy dedicated to medicinal cannabis products and to provide advice for consumers exploring alternative medical options offered by cannabis products. All spaces are staffed by associates who are highly trained on products sold in their display areas.

Ready to SHOWCASE your Brand? Click Here to Apply.

Click below to hear CalEthos’ President Piers Cooper discuss the CalEthos Event Center

Overall, the concept is compelling and a refreshing change from the typical dispensary environment. Southern California, with its advanced legal market, huge population, and trend-setting reputation, is a prime location for the SHOWCASE concept. Investors interested in learning more about the opportunity are encouraged to follow the links. The future of cannabis retail awaits.

For Additional Information on CalEthos Please Visit the website at: https://www.calethos.com

CalEthos

CEO Michael Campbell

[email protected]

714-352-5315

CFN Enterprises

President Frank Lane

206-369-7050

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Psychedelics are rapidly becoming both a mainstream treatment option and investment opportunity. With growing interest among researchers, forward-thinking companies are starting to build a presence in the space. 

In this article, we will take a look at the growing body of therapeutic evidence for psychedelics. How decriminalization is gaining ground, and how Ehave Inc. (OTC: EHVVF) along with other public companies are positioning themselves in the psychedelic space.

A Growing Body of Evidence

A growing body of evidence supports the use of psychedelics to treat a variety of different medical conditions. In 2016, Johns Hopkins researchers found that psilocybin produced a substantial and sustained decrease in depression and anxiety in cancer patients. A follow-up study on the same patients five years later found lasting effects from the one-time therapy.

The therapeutic evidence has become so overwhelming that Johns Hopkins established the Center for Psychedelic and Consciousness Research earlier this year to start rigorously investigating the drugs’ therapeutic potential. Researchers believe that it could have a beneficial impact on everything from smoking addiction to Alzheimer’s disease.

In addition to medical benefits, there’s plenty of anecdotal evidence that microdoses of psychedelics could improve mental health, well-being and productivity. Many prominent business leaders in Silicon Valley, including the late Steve Jobs, praised the benefits of microdosing psychedelics for creativity and cognition.

Click here to receive Ehave News and Investor Updates

Decriminalization Gain Ground

The growing interest among researchers has bolstered attempts by activists to decriminalize psychedelics throughout the country. Denver, Oakland and Santa Cruz have already decriminalized psychedelics over the past year, while California, Oregon and Iowa could see psychedelic-related measures on the ballot in November.

In the nation’s capital, Rep. Alexandria Ocasio-Cortez, D-NY recently introduced legislation that would allow researchers to more easily study the therapeutic and medicinal benefits of psilocybin and other psychedelics. These developments mirror what happened in the early medical cannabis industry where regulations were slowly relaxed over time.

It’s worth noting that these early efforts seek to decriminalize psychedelics and pave the way for research. Unlike the cannabis industry, there’s less interest in a recreational market and more interest in building a viable alternative therapy for countless different medical conditions that impact the brain—many without any current options.

Investors Start Taking Notice

Mind Medicine Inc. (NEO: MMED), better known as MindMed, became the first psychedelic pharmaceutical company to go public earlier this year on the NEO exchange. After raising $24.2 million in pre-public funding, the company plans to initially focus on addressing the opioid crisis and other forms of addiction with the use of psychedelics.

Click here to receive Ehave News and Investor Updates

Ehave Inc. (OTC: EHVVF) is another publicly-traded company in the space. Its Mycotopia Therapy subsidiary recently acquired PsychedeliTech and plans on hosting an inaugural PsyTech Summit in Tel Aviv, Israel on June 14-15, 2020. The conference will be modeled after the highly-successful CannaTech conference and connect key industry participants.

The company believes that it’s Dash platform will play a crucial role in the global advancement of psychedelic research. As a HIPAA and GDPR compliant platform, Dash is secure and compliant with some of the world’s strictest privacy laws. It’s an optimal way to compile psychedelic research and results to provide easy access for scientists globally.

Looking Ahead

Psychedelics are quickly picking up steam among both researchers and investors. As the market opens up, forward-thinking companies are building an early presence in the space before it grows into a large and mainstream industry. Cannabis investors may want to consider building a position in some of these companies given the similarities.

Please click here for additional Information on EHave, Inc. (OTC: EHVVF)

Please click here for additional Information on Mycotopia Therapy

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The COVID-19 outbreak has become a major source of stress over the past several weeks. In addition to the fear and anxiety of disease, quarantines and “stay at home” orders have contributed to stress levels, leading to poor sleep, unhealthy eating, and other side-effects. It’s important for everyone to take inventory of their health and take action.

Let’s take a look at some strategies to cope with these heightened stress and anxiety levels, as well as how cannabidiol (CBD) and adaptogens could play a role.

How to Reduce Stress & Anxiety

There are many different ways to cope with the fear and anxiety stemming from the COVID-19 outbreak. While some people already have good routines in place, others may have to build new habits and integrate them into a completely new lifestyle under lockdown. The good news is that there’s plenty of good advice from the experts.

The Centers for Disease Control (CDC) had several recommendations:

• Take breaks from watching, reading, or listening to news stories, including social media.
• Eat a healthy, well-balanced diet, exercise regularly (away from others), try to get plenty of sleep and avoid smoking cigarettes, alcohol and drugs.
• Connect with others remotely using voice calls or video chats and discuss how you’re feeling and any concerns.
• Take time to yourself and try new activities that you might enjoy.

Other common suggestions include:

• Practice mindfulness by focusing on the present moment from time to time.
• Limit access to stressors by refusing non-essential tasks that are stressful and allowing yourself to take breaks.
• Delegate some responsibilities to others where possible, such as asking children to do the dishes.

While most people have experienced an impact from the crisis, those with pre-existing mental health conditions should be especially cognizant of worsening symptoms. Parents should also monitor the stress levels of children and teens that may experience more intense feelings. Call your healthcare provider if stress gets in the way of your daily activities for several days.

Accredited? Click here to see Innoviom’s deck and learn more about the company’s current offering

CBD & Adaptogens Could Help

There are many different foods and beverages that have a demonstrated ability to promote relaxation and reduced stress levels.

Most people are familiar with the benefits of green tea, chamomile, lavender and lemon balm when it comes to stress reduction. These ingredients are often referred to as adaptogens — or non-toxic plants that help the body resist physical, chemical or biological stressors. Many of them have been used for centuries in Chinese and Ayurvedic healing traditions.

Cannabidiol, or CBD, has also become a popular wellness product over the past several months. In early stage studies, researchers found that CBD may alter serotonin signals that modulate feelings of anxiety and depression. A generalized anxiety disorder study, for instance, showed that CBD reduced stress in animals, such as rats.

Accredited? Click here to see Innoviom’s deck and learn more about the company’s current offering

Innoviom’s goal is to bring these ingredients to consumers through functional beverages. It’s flagship Tranquini® brand is a natural de-stress drink that contains a unique blend of these relaxing adaptogens. Meanwhile, Wowie by Tranquini® combines these adaptogens with hemp extract to provide an even greater relaxation effect.

Unlike other companies, Innoviom has taken the research into adaptogens and CBD and turned it into great tasting functional drinks — with a focus on the great tasting part! Tranquini® is distributed through U.S. chains, such as Meijer, and via distributors, such as KeHE and UNFI. Wowie is also being rolled out in jurisdictions where sales are permitted.

Follow us on social media:

Looking Ahead

Innoviom is led by CEO Ahmed El Azizi, former Global VP of Functional Beverages at PepsiCo, who has over 20 years of beverage experience. He’s joined by Group CFO Christine Morcos, who came from Pfizer, Gillette and P&G and Chief Growth Officer Julia Trofimova, a former employee of several consumer product companies, including RedBull.

The company’s experienced consumer products team recognized an emerging market opportunity and has the ability to execute on an aggressive growth plan.

Accredited investors interested in learning more about investing in Innoviom can sign up to receive its investor deck and offering details.

Accredited? Click here to see Innoviom’s deck and learn more about the company’s current offering

Statements not evaluated by the FDA.

Innoviom, Inc. Company Contact:

Ahmed Al Azizi CEO

[email protected]

CFN Media Contact:

Frank Lane President

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Israel has long been an international center for cannabis research. THC, the psychoactive ingredient in cannabis, and CBD, the plant’s predominant non-psychoactive ingredient, were first isolated and defined by Israeli researcher Dr. Raphael Mechoulam in the early 1960s. Research continued there in the following decades, and the Israeli government has contributed greatly to the country’s prominence in the global cannabis industry. 

In Israel, medical cannabis is legal while recreational use remains technically illegal, though the government decriminalized recreational use to some extent in 2017. Government agencies provide funding for cannabis research. In January 2019, the government passed a law to allow exports of medical cannabis, though the first export was announced a year later in January 2020. With that recent development, the table appears set for growth in the Israeli cannabis market. 

Click below to view more on Isracann Biosciences  – Israel’s First Pure Play Cannabis Firm

BOL Pharma is the Israeli company that announced the first export from the country, with a shipment destined for centers that specialize in the treatment of children with epilepsy and autism in the United Kingdom. The company’s CEO, Dr. Tamir Gedo, stated, “This is truly welcome news and a real breakthrough for the Israeli medical cannabis market. The Israeli cannabis industry has a huge competitive edge in the global arena, compared to many countries trying to enter the cannabis sector… Further opening of the market to exports will enable Israel to become a world leader in the coming years.”

Click Here To Receive Isracann’s Investor Presentation 

The UK legalized medical cannabis in late 2018. Since then, patients have had a hard time getting prescribed treatments in a timely fashion, with most of the supply coming from foreign countries but facing restrictive regulations. As a result, in early March 2020, the UK government announced a change in import restrictions designed to increase the flow of timely medicinal products to registered patients.

This dynamic is common throughout Europe, with countries adopting medical programs without the infrastructure, both regulatory and physical, to provide supply to its own patients. Israel, with its strategic location combined with governmental commitment to the industry, is in prime position to pick up some of the slack.

Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) is an Israeli-based cannabis company poised to enter both the Israeli domestic and the European export cannabis markets. The company is advancing its fully-funded 230,000 sq ft hybrid greenhouse cultivation project while also advancing a partnership with a late stage project consisting of approximately 200,000 sq ft of greenhouses located on over 880,000 sq ft of agricultural land. In conjunction with the cultivation projects, Isracann is developing European distribution channels while ensuring that all aspects of its business, from cultivation through processing and manufacturing, comply with European Union GMP regulations necessary for international trade. 

While laying the groundwork for an extensive European export operation, the company is certainly not foregoing the burgeoning domestic opportunity in Israel. The country, as of late 2019, had about 46,000 registered patients. Isracann expects this number to roughly double by the end of 2020, by which time the company hopes to be harvesting and distributing products.

The company recently announced a joint venture agreement with two near-term farm operations in the Sharon Plain region of Israel. The IMC-compliant farms operate under preliminary cannabis nursery and cultivation licenses and are preparing to commence planting within weeks with 160,000 sq. ft. of greenhouse canopy on two million sq. ft. of private land. The move paves the way for the company to ramp up sales faster than it expected and could help drive near- and long-term shareholder value.

In a recent two-part interview with CFN Media, Isracann Biosciences CEO Darryl Jones outlined the company’s strategy, assets, and partnerships. He talked about some of the advantages inherent in the Israeli market (ideal climate for cultivation, regulatory environment, advanced research, widespread domestic use, proximity to Europe, etc.). 

Click Here To Receive Isracann’s Investor Presentation 

Click Below to View Video Interview #1: Isracann Biosciences CEO Darryl Jones on Israel as a Cannabis Investment

Click Below to View Video Interview Part #2: Isracann Biosciences CEO Darryl Jones on How Israel became the Cannabis Research Capital of the World

The very first medical cannabis shipment from Israel to the UK marks a new era in the promising Israeli cannabis industry. With the country’s government backing research and development efforts, as well as implementing rules to encourage growth of the industry both domestically and internationally, Israel has cemented its place as a leader for the global cannabis market. The year ahead promises to be pivotal for both the industry in general, and for Isracann Biosciences in particular as the company executes its vision of a comprehensive farm-to-consumer cannabis company. Keep an eye out as the plan unfolds.

Click Here To Receive Isracann’s Investor Presentation

Click Here to Stay Up to Date with CFN Media, Your Premier Destination for Cannabis, CBD &  Psychedelic Financial Media

Isracann Biosciences Contact:

Investor Relations

Toll Free: +1 855.205.0266

CFN Media Contact:

Frank Lane President

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.